Malignant hematology disease
Conditions
Interventions
Group myeloid malignant disease ( Thiotepa combined with busulfan, fludarabine and venetoclaxe (TBFV) ):NA
Group Lymphoid malignant disease (Thiotepa combined with busulfan, fludarabine and cyclophosphamide (TBFC) ):NA
Sponsors
The First Affiliated Hospital of Ningbo University
Eligibility
Sex/Gender
All
Age
14 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. age 14-70 years (including 14 & 70 years); 2. an ECOG score of <3; 3. Liver function ALT or AST less than 2 times the upper limit of normal, renal function Cr less than 2 times the upper limit of normal and can tolerate high-dose chemotherapy; 4. Agreed to participate in the study protocol.
Exclusion criteria
Exclusion criteria: 1. Under 14 years of age or above 70 years of age; 2. Liver glutamic aminotransferase (ALT) or glutamic oxalacetic aminotransferase (AST) more than 2 times the upper limit of normal; 3. Cr value more than 2 times the upper limit of normal or intolerance of high-dose chemotherapy 4. During pregnant or breastfeeding period; 5. who are unable to cooperate with treatment in the transplantation compartment.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| graft-versus-host disease;CMV effective rate; | — |
Primary
| Measure | Time frame |
|---|---|
| 2 year OS;2 year DFS;relapse rate; | — |
Countries
China
Contacts
Public ContactPing Zhang
The First Affiliated Hospital of Ningbo University
Outcome results
None listed